Increasing Incidence of Spinal Muscular Atrophy Drives Demand for Gene Therapy Solutions: A Key Factor Shaping the Future of the Zolgensma Market in 2025

What combination of drivers is leading to accelerated growth in the zolgensma market?
The increasing incidence of spinal muscular atrophy (SMA) is expected to propel the growth of the Zolgensma market. SMA is a genetic disorder that causes progressive muscle weakness and atrophy, primarily affecting infants and young children. Improved genetic testing and newborn screening have led to earlier diagnoses, contributing to an increase in SMA cases. Zolgensma helps treat SMA by delivering a functional copy of the SMN1 gene, addressing the underlying genetic cause of the disease and helping to restore motor function and muscle strength. In August 2023, NHS England reported that around 70 children are born with SMA each year in the UK. This increasing incidence of SMA is fueling the growth of the Zolgensma market.

Get Your Zolgensma Market Report Here:
https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report

What is the projected compound annual growth rate (CAGR) of the zolgensma market from 2025 to 2034, and what factors influence it?
The Zolgensma market size has grown at XX (HCAGR) in recent years. It is expected to increase from $XX million in 2024 to $XX million in 2025, at a compound annual growth rate (CAGR) of XX%. The growth in the historic period is driven by the rising prevalence of spinal muscular atrophy, increased awareness of genetic disorders, rising healthcare expenditure, more genetic testing, and an increase in health insurance plans.

The zolgensma market is forecasted to grow at XX (FCAGR) over the next few years, reaching $XX million by 2029, with a CAGR of XX%. This growth is driven by the rising interest in personalized medicine, increasing global healthcare spending, the growth of telemedicine, greater focus on rare disease treatments, and advancements in digital health technologies. Trends to watch include advancements in gene therapy technologies, improvements in manufacturing processes, the development of new biomarkers, growth in digital health, and the development of intrathecal formulations.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp

How are the latest trends influencing the growth of the zolgensma market?
The prevailing trend in the Zolgensma market involves making strategic investments with an eye towards boosting production capacity, widening global reach, and hastening research and development operations for inventive gene therapy solutions. These investments work to bolster production capacity to meet the rising demand, propel advancements in gene therapy research and development, facilitate geographic extension to cater to more global patients, make supply chain processes more efficient, and promote collaborations that heighten awareness and availability of treatments. In April 2022, for example, the US Food and Drug Administration granted commercial licensure approval to the Swiss pharmaceutical corporation Novartis AG for its multi-product gene therapy manufacturing facility based in Durham, North Carolina. This licensing permits the 170,000-square-foot premises to conduct manufacturing, testing, and releasing of commercial Zolgensma, along with the production of gene therapy products for continuous and upcoming clinical trials. Furthermore, the facility will also back the production of gene therapy products set for current and future clinical trials.

What are the major segments of the zolgensma market and their role in driving growth?
The zolgensma market covered in this report is segmented -

1) By Indication: Spinal Muscular Atrophy (SMA) Type 1; Spinal Muscular Atrophy (SMA) Type 2; Spinal Muscular Atrophy (SMA) Type 3; Pre-symptomatic Spinal Muscular Atrophy (SMA)
2) By Age Group: Pediatric (Infants And Children); Adults
3) By Distribution Channel: Hospitals; Specialty Clinics; Pharmacies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20373

Which regions are key players in the growth of the zolgensma market?
North America was the largest region in the zolgensma market in 2024. The regions covered in the zolgensma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the zolgensma market?
Major companies operating in the zolgensma market are Novartis AG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20373&type=smp

What Is Covered In The Zolgensma Global Market Report?

•Market Size Forecast: Examine the zolgensma market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the zolgensma market for a structured understanding.
•Key Players Overview: Analyze major players in the zolgensma market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the zolgensma market.
•Segment Contributions: Evaluate how different segments drive overall growth in the zolgensma market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the zolgensma market.
•Industry Challenges: Identify potential risks and obstacles affecting the zolgensma market.
•Competitive Landscape: Review strategic developments in the zolgensma market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.